drugset / Trial / NCT00281593

Telmisartan (Micardis) and Ramipril (Altace) - Factorial Design Study for the Treatment of Hypertension

NCT00281593

Phase 3 Completed 1354 enrolled Boehringer Ingelheim
Treatment

Summary

To identify dose combinations of telmisartan and ramipril that are more effective in reducing diastolic blood pressure than each of the respective monotherapies in patients with Stage I or II hypertension.

Timeline

Start
2006-04
Primary completion
2007-04
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Ramipril Small molecule 1.25 mg
Subject Ramipril Small molecule 10 mg
Subject Ramipril Small molecule 20 mg
Subject Telmisartan Other / unclassified 20 mg
Subject Telmisartan Other / unclassified 80 mg

Indications